PMID: 11897931Mar 19, 2002Paper

Isoniazid-induced lupus erythematosus presenting with cardiac tamponade

American Journal of Therapeutics
Mumtaz A Siddiqui, Ijaz A Khan

Abstract

An estimated incidence of drug-induced lupus erythematosus caused by all drugs is 15,000 to 20,000 cases a year, and represents approximately 5 to 10% of the total number of patients with systemic lupus erythematosus. Approximately 22% of the patients treated with isoniazid for a mean of 6 months develop antinuclear antibodies. Isoniazid-induced lupus erythematosus affects either sex equally and the most common presenting feature is arthralgia or arthritis with anemia. Fever and pleuritis occur in approximately half of the cases, and pericarditis in approximately 30% of cases. IgG antibody to the (H2A-H2B)-DNA complex appears specific for the isoniazid-induced lupus erythematosus. The drug-induced lupus presenting with cardiac tamponade is a recognized feature of many drugs such as hydralazine, procainamide, and sulfasalazine. Reported here is a case of isoniazid-induced lupus erythematosus presenting with cardiac tamponade. A 73-year-old man was treated with isoniazid for 8 months at a dose of 300 mg a day. The patient responded to the withdrawal of the isoniazid therapy and placement of a pericardial window. The existing literature on the subject is reviewed.

References

Aug 1, 1975·Seminars in Arthritis and Rheumatism·S L Lee, P H CHase
May 1, 1978·Annals of Internal Medicine·N F RothfieldJ W Garfield
Sep 1, 1992·Annals of the Rheumatic Diseases·M Salazar-PáramoI García-De La Torre
Jan 22, 1966·Lancet·A Cannat, M Seligmann
Mar 1, 1972·Journal of Medical Genetics·D A EvansJ M Vetters
May 1, 1966·Archives of Internal Medicine·S L LeeM Siegel
Nov 1, 1982·Arthritis and Rheumatism·E M TanR J Winchester

❮ Previous
Next ❯

Citations

Jul 12, 2012·Japanese Journal of Clinical Oncology·Hidenori KidoTakuji Okusaka
Dec 2, 2011·Journal of Medical Case Reports·Vanja Varenika, Paul D Blanc
Nov 21, 2012·Actas dermo-sifiliográficas·M PretelA España
Oct 23, 2010·Joint, Bone, Spine : Revue Du Rhumatisme·Satoshi KuboYoshiya Tanaka
Dec 10, 2009·Revue de pneumologie clinique·J L RakotosonA C F Andrianarisoa
Apr 22, 2008·La Presse médicale·Monia Smiti KhanfirMohamed H Houman
Jul 6, 2004·Clinics in Dermatology·Dimitar AntonovNikolai Tsankov
Aug 16, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Payam NahidAndrew Vernon
Dec 13, 2006·Lupus·S Vasoo
Dec 24, 2005·Autoimmunity·Piercarlo Sarzi-PuttiniAndrea Doria
Jan 10, 2018·Medicinal Research Reviews·Přemysl MladěnkaUNKNOWN TOX-OER and CARDIOTOX Hradec Králové Researchers and Collaborators
Jul 12, 2019·The British Journal of Educational Psychology·Valérie PennequinCélia Maintenant
Aug 23, 2018·Revista Da Sociedade Brasileira De Medicina Tropical·Gao HuanSong Yan-Qing
Jan 14, 2017·Microbiology Spectrum·Shyam S Balepur, David Schlossberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Annals of the Rheumatic Diseases
M Salazar-PáramoI García-De La Torre
Archives of Dermatological Research
Camilla Dalle VedoveGiampiero Girolomoni
© 2022 Meta ULC. All rights reserved